Personalized Medicine and Imaging Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degrader
نویسندگان
چکیده
Purpose: Estrogen receptor (ER) targeting is key in management of receptor-positive breast cancer. Currently, there are no methods to optimize anti-ER therapy dosing. This study assesses the use of 16a-F-fluoroestradiol (F-FES) PET for fulvestrant dose optimization in a preclinical ERþ breast cancer model. Experimental Design: In vitro, F-FES retentionwas compared with ERa protein expression (ELISA) and ESR1 mRNA transcription (qPCR) in MCF7 cells (ERþ) after treatment with different fulvestrant doses.MCF7 xenografts were grown in ovariectomized nudemice and assigned to vehicle, low(0.05mg), medium(0.5 mg), or high-dose (5 mg) fulvestrant treatment groups (5–7 per group). Two and 3 days after fulvestrant treatment, PET/CT was performedusing F-FES and F-FDG, respectively. ER expression was assessed by immunohistochemistry, ELISA, and qPCR on xenografts. Tumor proliferation was assessed using Ki67 immunohistochemistry. Results: In vitro, we observed a parallel graded reduction in FFES uptake and ER expression with increased fulvestrant doses, despite enhancement of ERmRNA transcription. In xenografts, ER expression significantly decreasedwith increased fulvestrant dose, despite similar mRNA expression and Ki67 staining among the treatment groups. We observed a significant dose-dependent reduction of F-FES PET mean standardized uptake value (SUVmean) with fulvestrant treatment but no significant difference among the treatment groups in F-FDG PET SUVmean. Conclusions: We demonstrated that F-FES uptake mirrors the dose-dependent changes in functional ER expression with fulvestrant resulting in ER degradation and/or blockade; these precede changes in tumor metabolism and proliferation. Quantitative F-FES PET may be useful for tracking early efficacy of ER blockade/degradation and guiding ER-targeted therapy dosing in patientswithbreast cancer.ClinCancerRes;21(6);1340–7. 2015AACR.
منابع مشابه
Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
PURPOSE Estrogen receptor (ER) targeting is key in management of receptor-positive breast cancer. Currently, there are no methods to optimize anti-ER therapy dosing. This study assesses the use of 16α-(18)F-fluoroestradiol ((18)F-FES) PET for fulvestrant dose optimization in a preclinical ER(+) breast cancer model. EXPERIMENTAL DESIGN In vitro, (18)F-FES retention was compared with ERα protei...
متن کاملChanging Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study
A 65 year old male with metastatic colorectal cancer (mCRC) in the liver was referred for selective internal radionuclide therapy (SIRT) following a history of extensive systemic chemotherapy. 90Y PET imaging was performed immediately after treatment and used to confirm lesion targeting and measure individual lesion absorbed doses. Lesion dosimetry was highly predictive of eventual response in ...
متن کاملImaging features of estrogen-negative breast cancers: a correlation study with human epidermal growth factor type II overexpression
Background: Estrogen-negative breast cancers have different clinical course, prognostic features and treatment response in comparison to estrogen receptor-positive (ER-positive) breast cancers. Human epidermal growth factor receptor 2 (HER2) oncoprotein has found to have a pivotal role in natural cell growth and cell division and is suggested to be directly related to tumor invasiveness in brea...
متن کامل99mTc-MDP bone scan guides in the identification of mesenteric vein thrombosis
A 50-year-old man with postprandial abdominal pain, weight loss, and generalized body ache was referred to Nuclear medicine department for a whole body bone scan to look for any malignancy. Clinical examination did not reveal any specific positive findings. He underwent aTechnetium-99m Methylene Diphosphonate (99mTc-MDP) bone scan which showed no obvious bone pathology. But there was...
متن کاملA 99mTc-tricine-HYNIC-labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging
Melanocortin-1 (MC1) receptor is an attractive melanoma-specific target for the development of α-MSH peptide based imaging and therapeutic agents. In this work a new lactam bridge α-MSH analogue was synthesized and radiolabeled with 99mTc via HYNIC chelator and tricine as co-ligand. Also, stability in human serum, receptor bound internalization and tissue biodistribution in tumor bearing nude m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2015